[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644485":3},{"organization":4,"outcomesModule":7,"designInfo":31,"detailedDescription":38,"studyPopulation":22,"armGroups":39,"interventions":55,"overallOfficials":22,"centralContacts":91,"locations":22,"responsibleParty":97,"collaborators":22,"id":99,"slug":22,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":22,"eligibilityCriteria":104,"healthyVolunteers":100,"sex":105,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":22,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":22,"overallStatus":117,"whyStopped":22,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":123,"leadSponsor":125,"locationsCount":22},{"fullName":5,"class":6},"CSPC Megalith Biopharmaceutical Co.,Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":22},[9],{"measure":10,"description":11,"timeFrame":12},"Disease-Free Survival (DFS) assessed by the independent review committee (IRC)","DFS was defined as the time from randomization to either the date of disease recurrence or death (whatever the cause) as assessed by IRC per RECIST 1.1 or death (whatever the cause). Recurrence of disease was defined as local regional recurrence or a distant (metastatic) recurrence, confirmed by imaging and\u002For pathology. A second primary NSCLC was also considered to be an event.","Up to approximately 60 months",[14,17,20,24,27,29],{"measure":15,"description":16,"timeFrame":12},"Overall Survival (OS)","OS was defined as the time from randomization to the date of death(whatever the cause).",{"measure":18,"description":19,"timeFrame":12},"DFS assessed by investigators","DFS was defined as the time from randomization to either the date of disease recurrence as assessed by investigators per RECIST 1.1 or death (whatever the cause). Recurrence of disease was defined as local regional recurrence or a distant (metastatic) recurrence, confirmed by imaging and\u002For pathology. A second primary NSCLC was also considered to be an event.",{"measure":21,"description":22,"timeFrame":23},"Incidence and severity of Adverse Events (AEs)",null,"Approximately 15 months",{"measure":25,"description":22,"timeFrame":26},"EORTC QLQ-30 questionnaire","Approximately 13 months",{"measure":28,"description":22,"timeFrame":26},"Blood concentration of SYS6010 and Enlonstobart",{"measure":30,"description":22,"timeFrame":26},"Anti-drug Antibodies (ADAs) and Neutralizing Antibodies (Nabs)",{"allocation":32,"interventionModel":33,"interventionModelDescription":34,"primaryPurpose":35,"observationalModel":22,"timePerspective":22,"maskingInfo":36},"RANDOMIZED","PARALLEL","Randomized, open-label","TREATMENT",{"masking":37,"maskingDescription":22,"whoMasked":22},"NONE","This is a randomized, open-label, multicenter, Phase III clinical study. Participants with completely resected stage II-IIIB, actionable genomic alterations (AGAs) negative non-small cell lung cancer (NSCLC) who did not achieve a major pathological response (MPR) will be enrolled and randomized in a 1:1 ratio to experimental (SYS6010 + Enlonstobart) or control (Investigator's Choice of anti-PD-(L)-1 Monoclonal Antibody Regimen) group. Random factors include disease stage (Stage II \u002F IIIA vs. Stage IIIB), Pathological type (non-squamous cell carcinoma vs. squamous cell carcinoma), and lymph node status (positive vs. negative).",[40,46],{"label":41,"type":42,"description":22,"interventionNames":43},"SYS6010 + Enlonstobart","EXPERIMENTAL",[44,45],"Drug: SYS6010","Drug: Enlonstobart",{"label":47,"type":48,"description":22,"interventionNames":49},"Investigator's Choice of anti-PD-(L)-1 Monoclonal Antibody Regimen","ACTIVE_COMPARATOR",[50,51,52,53,54],"Drug: Tislelizumab","Drug: Toripalimab ±+platinum-based doublet chemotherapy","Drug: Durvalumab","Drug: Pembrolizumab","Drug: Nivolumab",[56,60,65,71,76,81,86],{"type":57,"name":58,"description":58,"armGroupLabels":59,"otherNames":22},"DRUG","SYS6010",[41],{"type":57,"name":61,"description":61,"armGroupLabels":62,"otherNames":63},"Enlonstobart",[41],[64],"SG001",{"type":57,"name":66,"description":67,"armGroupLabels":68,"otherNames":69},"Tislelizumab","administered via Intravenous (IV) injection",[47],[70],"BGB-A317",{"type":57,"name":72,"description":73,"armGroupLabels":74,"otherNames":75},"Toripalimab ±+platinum-based doublet chemotherapy","Cisplatin; Carboplatin; Pemetrexed; Paclitaxel;",[47],[73],{"type":57,"name":77,"description":77,"armGroupLabels":78,"otherNames":79},"Durvalumab",[47],[80],"MEDI4736",{"type":57,"name":82,"description":82,"armGroupLabels":83,"otherNames":84},"Pembrolizumab",[47],[85],"KEYTRUDA® MK-3475",{"type":57,"name":87,"description":87,"armGroupLabels":88,"otherNames":89},"Nivolumab",[47],[90],"Opdivo, BMS936558S",[92],{"name":93,"role":94,"phone":95,"phoneExt":22,"email":96},"Clinical Trials Information Group officer","CONTACT","031169085587","ctr-contact@cspc.cn",{"type":98,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100644485",false,"NCT07672223","A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)","A Phase III, Randomized, Open-Label Study of SYS6010 in Combination With Anti-PD-(L)-1 Monoclonal Antibody Versus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy for Patients With Completely Resected Stage II-IIIB NSCLC Who Have No Actionable Genomic Alterations and Not Achieved a Major Pathological Response.","Inclusion Criteria:\n\n1. Able to understand and willingness to voluntarily provide written informed consent.\n2. Age 18 to 75 years, males or females.\n3. Histologically confirmed squamous or non-squamous NSCLC.\n4. Ability to provide qualified tumor samples.\n5. Without actionable genomic alterations (AGAs), which should be tested at a local or central laboratory.\n6. Did not achieve a Major Pathological Response (MPR) as assessed by the Central Pathology Independent Review Committee (CPIRC).\n7. The International Association for the Study of Lung Cancer (IASLC) V9 Stage II-IIIB NSCLC, after confirmed complete surgical resection with resection margins proved microscopically free of disease (R0).\n\nExclusion Criteria:\n\n1. Participants with a condition requiring further surgical resection, in the investigator's opinion.\n2. Participants with diagnosis of stage IIIB with N3, and stage IIIC, IVA, and IVB NSCLC.\n3. Eligible only for incomplete resection.\n4. Participants with synchronous primary lung cancer or multiple primary malignancies, or a mixed histology of SCLC and NSCLC.\n5. History of hypersensitivity or contraindication to any active or inactive excipient of the study treatment.\n6. Prior or planned neoadjuvant or adjuvant radiotherapy for the current malignancy.\n\nNOTE: Other protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","18 Years","75 Years",{"count":109,"type":110},570,"ESTIMATED","INTERVENTIONAL",[113],"PHASE3","The purpose of the study is to compare the efficacy and safety of SYS6010 in combination with anti-PD-(L)-1 monoclonal antibody vs. anti-PD-(L)-1 monoclonal antibody as adjuvant therapy for patients with. with completely resected stage II-IIIB, actionable genomic alterations (AGAs) negative non-small cell lung cancer (NSCLC) who did not achieve a major pathological response (MPR).",[116],"Non-small Cell Lung Cancer","NOT_YET_RECRUITING","2026-06-25",{"date":120,"type":121},"2026-06-26","ACTUAL",{"date":118,"type":110},{"date":124,"type":110},"2031-11-30",{"name":5,"class":6}]